Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease (MJD), is an autosomal dominant neurodegenerative disorder that predominantly involves the cerebellar, pyramidal, extrapyramidal, motor neuron and oculomotor systems. SCA3 presents strong phenotypic heterogeneity and its causative mutation of SCA3 consists of an expansion of a CAG tract in exon 10 of the ATXN3 gene, situated at 14q32.1. The ATXN3 gene is ubiquitously expressed in neuronal and non-neuronal tissues, and also participates in cellular protein quality control pathways. Mutated ATXN3 alleles present about 45 to 87CAG repeats, which result in an expanded polyglutamine tract in ataxin-3. After mutation, the polyQ tract reaches the pathological threshold (about 50 glutamine residues); the protein is considered that it might gain a neurotoxic function through some unclear mechanisms. We reviewed the literature on the pathogenesis and therapeutic strategies of spinocerebellar ataxia type 3 patients. Conversion of the expanded protein is possible by enhancing protein refolding and degradation or preventing proteolytic cleavage and prevents the protein to reach the site of toxicity by altering its ability to translocate between the nucleus and cytoplasm. Proteasomal degradation and enhancing autophagic aggregate clearance are currently proposed remarkable therapy. In spite of extensive research, the molecular mechanisms of cellular toxicity resulting from mutant ataxin-3 remain no preventive treatment is currently available. These therapeutic strategies might be able to improve sign symptoms of SCA3 as well as slow the disease progression.
KeywordsSpinocerebellar Ataxia Type 3Machado-Joseph DiseasePolyglutamine DiseaseAtaxin-3Therapeutic Strategies
Evers, M.M., Tran, H.D., Zalachoras, I., Pepers, B.A., Meijer, O.C., den Dunnen, J.T., van Ommen, G.J., Aartsma-Rus, A. and van Roon-Mom, W.M. (2013) Ataxin-3 Protein Modification as a Treatment Strategy for Spinocerebellar Ataxia Type 3: Removal of the CAG Containing Exon. Neurobiology of Disease, 58, 49-56. https://doi.org/10.1016/j.nbd.2013.04.019
Takahashi, T., Katada, S. and Onodera, O. (2010) Polyglutamine Diseases: Where Does Toxicity Come from? What Is Toxicity? Where Are We Going? Journal of Molecular Cell Biology, 2, 180-191. https://doi.org/10.1093/jmcb/mjq005
Hansen, S.K., Borland, H., Hasholt, L.F., Tumer, Z., Nielsen, J.E., Rasmussen, M.A., Nielsen, T.T., Stummann, T.C., Fog, K. and Hyttel, P. (2016) Generation of Spinocerebellar Ataxia Type 3 Patient-Derived Induced Pluripotent Stem Cell Line SCA3.B11. Stem Cell Research, 16, 589-592. https://doi.org/10.1016/j.scr.2016.02.042
Li, L.B., Yu, Z., Teng, X. and Bonini, N.M. (2008) RNA Toxicity Is a Component of Ataxin-3 Degeneration in Drosophila. Nature, 453, 1107-1111. https://doi.org/10.1038/nature06909
Nobrega, C., Nascimento-Ferreira, I., Onofre, I., Albuquerque, D., Hirai, H., Deglon, N. and de Almeida, L.P. (2013) Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice. PLoS ONE, 8, e52396. https://doi.org/10.1371/journal.pone.0052396
Gales, L., Cortes, L., Almeida, C., Melo, C.V., Costa, M.C., Maciel, P., Clarke, D.T., Damas, A.M. and Macedo-Ribeiro, S. (2005) Towards a Structural Understanding of the Fibrillization Pathway in Machado-Joseph’s Disease: Trapping Early Oligomers of Non-Expanded Ataxin-3. Journal of Molecular Biology, 353, 642-654. https://doi.org/10.1016/j.jmb.2005.08.061
Tzvetkov, N. and Breuer, P. (2007) Josephin Domain-Containing Proteins from a Variety of Species Are Active de-Ubiquitination Enzymes. Biological Chemistry, 388, 973-978. https://doi.org/10.1515/BC.2007.107
Albrecht, M., Golatta, M., Wullner, U. and Lengauer, T. (2004) Structural and Functional Analysis of Ataxin-2 and Ataxin-3. European Journal of Biochemistry, 271, 3155-3170. https://doi.org/10.1111/j.1432-1033.2004.04245.x
Riess, O., Rub, U., Pastore, A., Bauer, P. and Schols, L. (2008) SCA3: Neurological Features, Pathogenesis and Animal Models. Cerebellum (London, England), 7, 125-137. https://doi.org/10.1007/s12311-008-0013-4
Nijman, S.M., Luna-Vargas, M.P., Velds, A., Brummelkamp, T.R., Dirac, A.M., Sixma, T.K. and Bernards, R. (2005) A Genomic and Functional Inventory of Deubiquitinating Enzymes. Cell, 123, 773-786. https://doi.org/10.1016/j.cell.2005.11.007
Todi, S.V., Winborn, B.J., Scaglione, K.M., Blount, J.R., Travis, S.M. and Paulson, H.L. (2009) Ubiquitination Directly Enhances Activity of the Deubiquitinating Enzyme Ataxin-3. The EMBO Journal, 28, 372-382. https://doi.org/10.1038/emboj.2008.289
Ferro, A., Carvalho, A.L., Teixeira-Castro, A., Almeida, C., Tome, R.J., Cortes, L., Rodrigues, A.J., Logarinho, E., Sequeiros, J., Macedo-Ribeiro, S. and Maciel, P. (2007) NEDD8: A New Ataxin-3 Interactor. Biochimica et Biophysica Acta, 1773, 1619-1627. https://doi.org/10.1016/j.bbamcr.2007.07.012
Li, F., Macfarlan, T., Pittman, R.N. and Chakravarti, D. (2002) Ataxin-3 Is a Histone-Binding Protein with Two Independent Transcriptional Corepressor Activities. The Journal of Biological Chemistry, 277, 45004-45012. https://doi.org/10.1074/jbc.M205259200
Haacke, A., Broadley, S.A., Boteva, R., Tzvetkov, N., Hartl, F.U. and Breuer, P. (2006) Proteolytic Cleavage of Polyglutamine-Expanded Ataxin-3 Is Critical for Aggregation and Sequestration of Non-Expanded Ataxin-3. Human Molecular Genetics, 15, 555-568. https://doi.org/10.1093/hmg/ddi472
Berke, S.J., Schmied, F.A., Brunt, E.R., Ellerby, L.M. and Paulson, H.L. (2004) Caspase-Mediated Proteolysis of the Polyglutamine Disease Protein Ataxin-3. Journal of Neurochemistry, 89, 908-918. https://doi.org/10.1111/j.1471-4159.2004.02369.x
Koch, P., Breuer, P., Peitz, M., Jungverdorben, J., Kesavan, J., Poppe, D., Doerr, J., Ladewig, J., Mertens, J., Tuting, T., Hoffmann, P., Klockgether, T., Evert, B.O., Wullner, U. and Brustle, O. (2011) Excitation-Induced Ataxin-3 Aggregation in Neurons from Patients with Machado-Joseph Disease. Nature, 480, 543-546. https://doi.org/10.1038/nature10671
Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M. and Onodera, O. (2008) Soluble Polyglutamine Oligomers Formed Prior to Inclusion Body Formation Are Cytotoxic. Human Molecular Genetics, 17, 345-356. https://doi.org/10.1093/hmg/ddm311
Goti, D., Katzen, S.M., Mez, J., Kurtis, N., Kiluk, J., Ben-Haiem, L., Jenkins, N.A., Copeland, N.G., Kakizuka, A., Sharp, A.H., Ross, C.A., Mouton, P.R. and Colomer, V. (2004) A Mutant Ataxin-3 Putative-Cleavage Fragment in Brains of Machado-Joseph Disease Patients and Transgenic Mice Is Cytotoxic above a Critical Concentration. The Journal of Neuroscience, 24, 10266-10279. https://doi.org/10.1523/JNEUROSCI.2734-04.2004
Hubener, J., Weber, J.J., Richter, C., Honold, L., Weiss, A., Murad, F., Breuer, P., Wullner, U., Bellstedt, P., Paquet-Durand, F., Takano, J., Saido, T.C., Riess, O. and Nguyen, H.P. (2013) Calpain-Mediated Ataxin-3 Cleavage in the Molecular Pathogenesis of Spinocerebellar Ataxia Type 3 (SCA3). Human Molecular Genetics, 22, 508-518. https://doi.org/10.1093/hmg/dds449
Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S. and Kakizuka, A. (1996) Expanded Polyglutamine in the Machado-Joseph Disease Protein Induces Cell Death in Vitro and in Vivo. Nature Genetics, 13, 196-202. https://doi.org/10.1038/ng0696-196
Teixeira-Castro, A., Ailion, M., Jalles, A., Brignull, H.R., Vilaca, J.L., Dias, N., Rodrigues, P., Oliveira, J.F., Neves-Carvalho, A., Morimoto, R.I. and Maciel, P. (2011) Neuron-Specific Proteotoxicity of Mutant Ataxin-3 in C. elegans: Rescue by the DAF-16 and HSF-1 Pathways. Human Molecular Genetics, 20, 2996-3009. https://doi.org/10.1093/hmg/ddr203
Burnett, B.G. and Pittman, R.N. (2005) The Polyglutamine Neurodegenerative Protein Ataxin 3 Regulates Aggresome Formation. Proceedings of the National Academy of Sciences of the United States of America, 102, 4330-4335. https://doi.org/10.1073/pnas.0407252102
Paulson, H. (2012) Machado-Joseph Disease/Spinocerebellar Ataxia Type 3. In: Handbook of Clinical Neurology, Vol. 103, Elsevier, Amsterdam, 437-449. https://doi.org/10.1016/B978-0-444-51892-7.00027-9
Rodrigues, A.J., do Carmo Costa, M., Silva, T.L., Ferreira, D., Bajanca, F., Logarinho, E. and Maciel, P. (2010) Absence of Ataxin-3 Leads to Cytoskeletal Disorganization and Increased Cell Death. Biochimica et Biophysica Acta, 1803, 1154-1163. https://doi.org/10.1016/j.bbamcr.2010.07.004
do Carmo Costa, M., Bajanca, F., Rodrigues, A.J., Tome, R.J., Corthals, G., Macedo-Ribeiro, S., Paulson, H.L., Logarinho, E. and Maciel, P. (2010) Ataxin-3 Plays a Role in Mouse Myogenic Differentiation through Regulation of Integrin Subunit Levels. PLoS ONE, 5, e11728. https://doi.org/10.1371/journal.pone.0011728
Paulson, H.L., Das, S.S., Crino, P.B., Perez, M.K., Patel, S.C., Gotsdiner, D., Fischbeck, K.H. and Pittman, R.N. (1997) Machado-Joseph Disease Gene Product Is a Cytoplasmic Protein Widely Expressed in Brain. Annals of Neurology, 41, 453-462. https://doi.org/10.1002/ana.410410408
Mauri, P.L., Riva, M., Ambu, D., De Palma, A., Secundo, F., Benazzi, L., Valtorta, M., Tortora, P. and Fusi, P. (2006) Ataxin-3 Is Subject to Autolytic Cleavage. The FEBS Journal, 273, 4277-4286. https://doi.org/10.1111/j.1742-4658.2006.05419.x
Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subramony, S.H., Das, S.S., Vig, P., Mandel, J.L., Fischbeck, K.H. and Pittman, R.N. (1997) Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3. Neuron, 19, 333-344. https://doi.org/10.1016/S0896-6273(00)80943-5
Schmidt, T., Lindenberg, K.S., Krebs, A., Schols, L., Laccone, F., Herms, J., Rechsteiner, M., Riess, O. and Landwehrmeyer, G.B. (2002) Protein Surveillance Machinery in Brains with Spinocerebellar Ataxia Type 3: Redistribution and Differential Recruitment of 26S Proteasome Subunits and Chaperones to Neuronal Intranuclear Inclusions. Annals of Neurology, 51, 302-310. https://doi.org/10.1002/ana.10101
Horimoto, Y., Matsumoto, M., Akatsu, H., Kojima, A., Yoshida, M., Nokura, K., Yuasa, H., Katada, E., Yamamoto, T., Kosaka, K., Hashizume, Y., Yamamoto, H. and Mitake, S. (2011) Longitudinal Study on MRI Intensity Changes of Machado-Joseph Disease: Correlation between MRI Findings and Neuropathological Changes. Journal of Neurology, 258, 1657-1664. https://doi.org/10.1007/s00415-011-5992-2
Evert, B.O., Schelhaas, J., Fleischer, H., de Vos, R.A., Brunt, E.R., Stenzel, W., Klockgether, T. and Wullner, U. (2006) Neuronal Intranuclear Inclusions, Dysregulation of Cytokine Expression and Cell Death in Spinocerebellar Ataxia Type 3. Clinical Neuropathology, 25, 272-281.
Rub, U., de Vos, R.A., Brunt, E.R., Sebesteny, T., Schols, L., Auburger, G., Bohl, J., Ghebremedhin, E., Gierga, K., Seidel, K., den Dunnen, W., Heinsen, H., Paulson, H. and Deller, T. (2006) Spinocerebellar Ataxia Type 3 (SCA3): Thalamic Neurodegeneration Occurs Independently from Thalamic Ataxin-3 Immunopositive Neuronal Intranuclear Inclusions. Brain Pathology (Zurich, Switzerland), 16, 218-227. https://doi.org/10.1111/j.1750-3639.2006.00022.x
Ajayi, A., Yu, X., Lindberg, S., Langel, U. and Strom, A.L. (2012) Expanded Ataxin-7 Cause Toxicity by Inducing ROS Production from NADPH Oxidase Complexes in a Stable Inducible Spinocerebellar Ataxia Type 7 (SCA7) Model. BMC Neuroscience, 13, Article No. 86. https://doi.org/10.1186/1471-2202-13-86
Goswami, A., Dikshit, P., Mishra, A., Mulherkar, S., Nukina, N. and Jana, N.R. (2006) Oxidative Stress Promotes Mutant Huntingtin Aggregation and Mutant Huntingtin-Dependent Cell Death by Mimicking Proteasomal Malfunction. Biochemical and Biophysical Research Communications, 342, 184-190. https://doi.org/10.1016/j.bbrc.2006.01.136
Kim, S.J., Kim, T.S., Hong, S., Rhim, H., Kim, I.Y. and Kang, S. (2003) Oxidative Stimuli Affect Polyglutamine Aggregation and Cell Death in Human Mutant Ataxin-1-Expressing Cells. Neuroscience Letters, 348, 21-24. https://doi.org/10.1016/S0304-3940(03)00657-8
Miyata, R., Hayashi, M., Tanuma, N., Shioda, K., Fukatsu, R. and Mizutani, S. (2008) Oxidative Stress in Neurodegeneration in Dentatorubral-Pallidoluysian Atrophy. Journal of the Neurological Sciences, 264, 133-139. https://doi.org/10.1016/j.jns.2007.08.025
Yu, Y.C., Kuo, C.L., Cheng, W.L., Liu, C.S. and Hsieh, M. (2009) Decreased Antioxidant Enzyme Activity and Increased Mitochondrial DNA Damage in Cellular Models of Machado-Joseph Disease. Journal of Neuroscience Research, 87, 1884-1891. https://doi.org/10.1002/jnr.22011
Kazachkova, N., Raposo, M., Montiel, R., Cymbron, T., Bettencourt, C., Silva-Fernandes, A., Silva, S., Maciel, P. and Lima, M. (2013) Patterns of Mitochondrial DNA Damage in Blood and Brain Tissues of a Transgenic Mouse Model of Machado-Joseph Disease. Neuro-Degenerative Diseases, 11, 206-214. https://doi.org/10.1159/000339207
Laco, M.N., Oliveira, C.R., Paulson, H.L. and Rego, A.C. (2012) Compromised Mitochondrial Complex II in Models of Machado-Joseph Disease. Biochimica et Biophysica Acta, 1822, 139-149. https://doi.org/10.1016/j.bbadis.2011.10.010
Emerit, J., Edeas, M. and Bricaire, F. (2004) Neurodegenerative Diseases and Oxidative Stress. Biomedicine & Pharmacotherapy, 58, 39-46. https://doi.org/10.1016/j.biopha.2003.11.004
Evers, M.M., Toonen, L.J. and van Roon-Mom, W.M. (2014) Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies. Molecular Neurobiology, 49, 1513-1531. https://doi.org/10.1007/s12035-013-8596-2
Sopher, B.L., Ladd, P.D., Pineda, V.V., Libby, R.T., Sunkin, S.M., Hurley, J.B., Thienes, C.P., Gaasterland, T., Filippova, G.N. and La Spada, A.R. (2011) CTCF Regulates Ataxin-7 Expression through Promotion of a Convergently Transcribed, Antisense Noncoding RNA. Neuron, 70, 1071-1084. https://doi.org/10.1016/j.neuron.2011.05.027
He, Y., Vogelstein, B., Velculescu, V.E., Papadopoulos, N. and Kinzler, K.W. (2008) The Antisense Transcriptomes of Human Cells. Science, 322, 1855-1857. https://doi.org/10.1126/science.1163853
Banez-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I., Guzman, M., Estivill, X. and Marti, E. (2012) A Pathogenic Mechanism in Huntington’s Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity. PLoS Genetics, 8, e1002481. https://doi.org/10.1371/journal.pgen.1002481
Zu, T., Gibbens, B., Doty, N.S., Gomes-Pereira, M., Huguet, A., Stone, M.D., Margolis, J., Peterson, M., Markowski, T.W., Ingram, M.A., Nan, Z., Forster, C., Low, W.C., Schoser, B., Somia, N.V., Clark, H.B., Schmechel, S., Bitterman, P.B., Gourdon, G., Swanson, M.S., Moseley, M. and Ranum, L.P. (2011) Non-ATG-Initiated Translation Directed by Microsatellite Expansions. Proceedings of the National Academy of Sciences of the United States of America, 108, 260-265. https://doi.org/10.1073/pnas.1013343108
Pearson, C.E. (2011) Repeat Associated Non-ATG Translation Initiation: One DNA, Two Transcripts, Seven Reading Frames, Potentially Nine Toxic Entities! PLoS Genetics, 7, e1002018. https://doi.org/10.1371/journal.pgen.1002018
Bezprozvanny, I. and Klockgether, T. (2009) Therapeutic Prospects for Spinocerebellar Ataxia Type 2 and 3. Drugs of the Future, 34.
Shao, J. and Diamond, M.I. (2007) Polyglutamine Diseases: Emerging Concepts in Pathogenesis and Therapy. Human Molecular Genetics, 16, R115-R123. https://doi.org/10.1093/hmg/ddm213
Johri, A. and Beal, M.F. (2012) Antioxidants in Huntington’s Disease. Biochimica et Biophysica Acta, 1822, 664-674. https://doi.org/10.1016/j.bbadis.2011.11.014
Hersch, S.M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., Ulug, A.M., Beal, M.F., Matson, W., Bogdanov, M., Ebbel, E., Zaleta, A., Kaneko, Y., Jenkins, B., Hevelone, N., Zhang, H., Yu, H., Schoenfeld, D., Ferrante, R. and Rosas, H.D. (2006) Creatine in Huntington Disease Is Safe, Tolerable, Bioavailable in Brain and Reduces Serum 8OH2’dG. Neurology, 66, 250-252. https://doi.org/10.1212/01.wnl.0000194318.74946.b6
Lo, R.Y., Figueroa, K.P., Pulst, S.M., Lin, C.Y., Perlman, S., Wilmot, G., Gomez, C., Schmahmann, J., Paulson, H., Shakkottai, V.G., Ying, S., Zesiewicz, T., Bushara, K., Geschwind, M., Xia, G., Subramony, S.H., Ashizawa, T. and Kuo, S.H. (2015) Coenzyme Q10 and Spinocerebellar Ataxias. Movement Disorders, 30, 214-220. https://doi.org/10.1002/mds.26088
Chou, A.H., Yeh, T.H., Ouyang, P., Chen, Y.L., Chen, S.Y. and Wang, H.L. (2008) Polyglutamine-Expanded Ataxin-3 Causes Cerebellar Dysfunction of SCA3 Transgenic Mice by Inducing Transcriptional Dysregulation. Neurobiology of Disease, 31, 89-101. https://doi.org/10.1016/j.nbd.2008.03.011
Chou, A.H., Chen, S.Y., Yeh, T.H., Weng, Y.H. and Wang, H.L. (2011) HDAC Inhibitor Sodium Butyrate Reverses Transcriptional Downregulation and Ameliorates Ataxic Symptoms in a Transgenic Mouse Model of SCA3. Neurobiology of Disease, 41, 481-488. https://doi.org/10.1016/j.nbd.2010.10.019
Minamiyama, M., Katsuno, M., Adachi, H., Waza, M., Sang, C., Kobayashi, Y., Tanaka, F., Doyu, M., Inukai, A. and Sobue, G. (2004) Sodium Butyrate Ameliorates Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy. Human Molecular Genetics, 13, 1183-1192. https://doi.org/10.1093/hmg/ddh131
Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A., Steffan, J.S., Marsh, J.L., Thompson, L.M., Lewis, C.M., Marks, P.A. and Bates, G.P. (2003) Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor, Ameliorates Motor Deficits in a Mouse Model of Huntington’s Disease. Proceedings of the National Academy of Sciences of the United States of America, 100, 2041-2046. https://doi.org/10.1073/pnas.0437870100
Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N.W., Ratan, R.R., Luthi-Carter, R. and Hersch, S.M. (2003) Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington’s Disease Mice. The Journal of Neuroscience, 23, 9418-9427. https://doi.org/10.1523/JNEUROSCI.23-28-09418.2003
Gardian, G., Browne, S.E., Choi, D.K., Klivenyi, P., Gregorio, J., Kubilus, J.K., Ryu, H., Langley, B., Ratan, R.R., Ferrante, R.J. and Beal, M.F. (2005) Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington’s Disease. The Journal of Biological Chemistry, 280, 556-563. https://doi.org/10.1074/jbc.M410210200
Ying, M., Xu, R., Wu, X., Zhu, H., Zhuang, Y., Han, M. and Xu, T. (2006) Sodium Butyrate Ameliorates Histone Hypoacetylation and Neurodegenerative Phenotypes in a Mouse Model for DRPLA. The Journal of Biological Chemistry, 281, 12580-12586. https://doi.org/10.1074/jbc.M511677200
Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M., Kurokawa, R., Housman, D.E., Jackson, G.R., Marsh, J.L. and Thompson, L.M. (2001) Histone Deacetylase Inhibitors Arrest Polyglutamine-Dependent Neurodegeneration in Drosophila. Nature, 413, 739-743. https://doi.org/10.1038/35099568
Lei, L.F., Yang, G.P., Wang, J.L., Chuang, D.M., Song, W.H., Tang, B.S. and Jiang, H. (2016) Safety and Efficacy of Valproic Acid Treatment in SCA3/MJD Patients. Parkinsonism & Related Disorders, 26, 55-61. https://doi.org/10.1016/j.parkreldis.2016.03.005
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.F. and Yao, T.P. (2002) HDAC6 Is a Microtubule-Associated Deacetylase. Nature, 417, 455-458. https://doi.org/10.1038/417455a
Kovacs, J.J., Murphy, P.J., Gaillard, S., Zhao, X., Wu, J.T., Nicchitta, C.V., Yoshida, M., Toft, D.O., Pratt, W.B. and Yao, T.P. (2005) HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor. Molecular Cell, 18, 601-607. https://doi.org/10.1016/j.molcel.2005.04.021
Ren, M., Leng, Y., Jeong, M., Leeds, P.R. and Chuang, D.M. (2004) Valproic Acid Reduces Brain Damage Induced by Transient Focal Cerebral Ischemia in Rats: Potential Roles of Histone Deacetylase Inhibition and Heat Shock Protein Induction. Journal of Neurochemistry, 89, 1358-1367. https://doi.org/10.1111/j.1471-4159.2004.02406.x
Zhao, Y., Sun, H., Lu, J., Li, X., Chen, X., Tao, D., Huang, W. and Huang, B. (2005) Lifespan Extension and Elevated hsp Gene Expression in Drosophila Caused by Histone Deacetylase Inhibitors. The Journal of Experimental Biology, 208, 697-705. https://doi.org/10.1242/jeb.01439
Alves, S., Nascimento-Ferreira, I., Dufour, N., Hassig, R., Auregan, G., Nobrega, C., Brouillet, E., Hantraye, P., Pedroso de Lima, M.C., Deglon, N. and de Almeida, L.P. (2010) Silencing Ataxin-3 Mitigates Degeneration in a Rat Model of Machado-Joseph Disease: No Role for Wild-Type Ataxin-3? Human Molecular Genetics, 19, 2380-2394. https://doi.org/10.1093/hmg/ddq111
Rodriguez-Lebron, E. and Paulson, H.L. (2006) Allele-Specific RNA Interference for Neurological Disease. Gene Therapy, 13, 576-581. https://doi.org/10.1038/sj.gt.3302702
Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L. and Paulson, H.L. (2003) Allele-Specific Silencing of Dominant Disease Genes. Proceedings of the National Academy of Sciences of the United States of America, 100, 7195-7200. https://doi.org/10.1073/pnas.1231012100
Alves, S., Nascimento-Ferreira, I., Auregan, G., Hassig, R., Dufour, N., Brouillet, E., Pedroso de Lima, M.C., Hantraye, P., Pereira de Almeida, L. and Deglon, N. (2008) Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease. PLoS ONE, 3, e3341. https://doi.org/10.1371/journal.pone.0003341
Gaspar, C., Lopes-Cendes, I., Hayes, S., Goto, J., Arvidsson, K., Dias, A., Silveira, I., Maciel, P., Coutinho, P., Lima, M., Zhou, Y.X., Soong, B.W., Watanabe, M., Giunti, P., Stevanin, G., Riess, O., Sasaki, H., Hsieh, M., Nicholson, G.A., Brunt, E., Higgins, J.J., Lauritzen, M., Tranebjaerg, L., Volpini, V., Wood, N., Ranum, L., Tsuji, S., Brice, A., Sequeiros, J. and Rouleau, G.A. (2001) Ancestral Origins of the Machado-Joseph Disease Mutation: A Worldwide Haplotype Study. American Journal of Human Genetics, 68, 523-528. https://doi.org/10.1086/318184
Xia, H., Mao, Q., Eliason, S.L., Harper, S.Q., Martins, I.H., Orr, H.T., Paulson, H.L., Yang, L., Kotin, R.M. and Davidson, B.L. (2004) RNAi Suppresses Polyglutamine-Induced Neurodegeneration in a Model of Spinocerebellar Ataxia. Nature Medicine, 10, 816-820. https://doi.org/10.1038/nm1076
Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Martins, I.H., Mao, Q., Yang, L., Kotin, R.M., Paulson, H.L. and Davidson, B.L. (2005) RNA Interference Improves Motor and Neuropathological Abnormalities in a Huntington’s Disease Mouse Model. Proceedings of the National Academy of Sciences of the United States of America, 102, 5820-5825. https://doi.org/10.1073/pnas.0501507102
Liu, J., Pendergraff, H., Narayanannair, K.J., Lackey, J.G., Kuchimanchi, S., Rajeev, K.G., Manoharan, M., Hu, J. and Corey, D.R. (2013) RNA Duplexes with Abasic Substitutions Are Potent and Allele-Selective Inhibitors of Huntingtin and Ataxin-3 Expression. Nucleic Acids Research, 41, 8788-8801. https://doi.org/10.1093/nar/gkt594
Liu, J., Yu, D., Aiba, Y., Pendergraff, H., Swayze, E.E., Lima, W.F., Hu, J., Prakash, T.P. and Corey, D.R. (2013) ss-siRNAs Allele Selectively Inhibit Ataxin-3 Expression: Multiple Mechanisms for an Alternative Gene Silencing Strategy. Nucleic Acids Research, 41, 9570-9583. https://doi.org/10.1093/nar/gkt693
Hu, J., Gagnon, K.T., Liu, J., Watts, J.K., Syeda-Nawaz, J., Bennett, C.F., Swayze, E.E., Randolph, J., Chattopadhyaya, J. and Corey, D.R. (2011) Allele-Selective Inhibition of Ataxin-3 (ATX3) Expression by Antisense Oligomers and Duplex RNAs. Biological Chemistry, 392, 315-325. https://doi.org/10.1515/bc.2011.045
Spitali, P. and Aartsma-Rus, A. (2012) Splice Modulating Therapies for Human Disease. Cell, 148, 1085-1088. https://doi.org/10.1016/j.cell.2012.02.014
Zalachoras, I., Evers, M.M., van Roon-Mom, W.M., Aartsma-Rus, A.M. and Meijer, O.C. (2011) Antisense-Mediated RNA Targeting: Versatile and Expedient Genetic Manipulation in the Brain. Frontiers in Molecular Neuroscience, 4, 10. https://doi.org/10.3389/fnmol.2011.00010
Wellington, C.L. and Hayden, M.R. (2000) Caspases and Neurodegeneration: On the Cutting Edge of New Therapeutic Approaches. Clinical Genetics, 57, 1-10. https://doi.org/10.1034/j.1399-0004.2000.570101.x
Tarlac, V. and Storey, E. (2003) Role of Proteolysis in Polyglutamine Disorders. Journal of Neuroscience Research, 74, 406-416. https://doi.org/10.1002/jnr.10746
Di Prospero, N.A. and Fischbeck, K.H. (2005) Therapeutics Development for Triplet Repeat Expansion Diseases. Nature Reviews Genetics, 6, 756-766. https://doi.org/10.1038/nrg1690
Ona, V.O., Li, M., Vonsattel, J.P., Andrews, L.J., Khan, S.Q., Chung, W.M., Frey, A.S., Menon, A.S., Li, X.J., Stieg, P.E., Yuan, J., Penney, J.B., Young, A.B., Cha, J.H. and Friedlander, R.M. (1999) Inhibition of Caspase-1 Slows Disease Progression in a Mouse Model of Huntington’s Disease. Nature, 399, 263-267. https://doi.org/10.1038/20446
Li, Z. and Sheng, M. (2012) Caspases in Synaptic Plasticity. Molecular Brain, 5, Article No. 15. https://doi.org/10.1186/1756-6606-5-15
Troy, C.M. and Salvesen, G.S. (2002) Caspases on the Brain. Journal of Neuroscience Research, 69, 145-150. https://doi.org/10.1002/jnr.10294
Haacke, A., Hartl, F.U. and Breuer, P. (2007) Calpain Inhibition Is Sufficient to Suppress Aggregation of Polyglutamine-Expanded Ataxin-3. The Journal of Biological Chemistry, 282, 18851-18856. https://doi.org/10.1074/jbc.M611914200
Simoes, A.T., Goncalves, N., Koeppen, A., Deglon, N., Kugler, S., Duarte, C.B. and Pereira de Almeida, L. (2012) Calpastatin-Mediated Inhibition of Calpains in the Mouse Brain Prevents Mutant Ataxin 3 Proteolysis, Nuclear Localization and Aggregation, Relieving Machado-Joseph Disease. Brain, 135, 2428-2439. https://doi.org/10.1093/brain/aws177
Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Pagoulatos, G., Angelidis, C., Kusakabe, M., Yoshiki, A., Kobayashi, Y., Doyu, M. and Sobue, G. (2003) Heat Shock Protein 70 Chaperone Overexpression Ameliorates Phenotypes of the Spinal and Bulbar Muscular Atrophy Transgenic Mouse Model by Reducing Nuclear-Localized Mutant Androgen Receptor Protein. The Journal of Neuroscience, 23, 2203-2211. https://doi.org/10.1523/JNEUROSCI.23-06-02203.2003
Cummings, C.J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H.T., Dillmann, W.H. and Zoghbi, H.Y. (2001) Over-Expression of Inducible HSP70 Chaperone Suppresses Neuropathology and Improves Motor Function in SCA1 Mice. Human Molecular Genetics, 10, 1511-1518. https://doi.org/10.1093/hmg/10.14.1511
Sittler, A., Lurz, R., Lueder, G., Priller, J., Lehrach, H., Hayer-Hartl, M.K., Hartl, F.U. and Wanker, E.E. (2001) Geldanamycin Activates a Heat Shock Response and Inhibits Huntingtin Aggregation in a Cell Culture Model of Huntington’s Disease. Human Molecular Genetics, 10, 1307-1315. https://doi.org/10.1093/hmg/10.12.1307
Hay, D.G., Sathasivam, K., Tobaben, S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D.L., Woodman, B. and Bates, G.P. (2004) Progressive Decrease in Chaperone Protein Levels in a Mouse Model of Huntington’s Disease and Induction of Stress Proteins as a Therapeutic Approach. Human Molecular Genetics, 13, 1389-1405. https://doi.org/10.1093/hmg/ddh144
Katsuno, M., Sang, C., Adachi, H., Minamiyama, M., Waza, M., Tanaka, F., Doyu, M. and Sobue, G. (2005) Pharmacological Induction of Heat-Shock Proteins Alleviates Polyglutamine-Mediated Motor Neuron Disease. Proceedings of the National Academy of Sciences of the United States of America, 102, 16801-16806. https://doi.org/10.1073/pnas.0506249102
Chan, H.Y., Warrick, J.M., Gray-Board, G.L., Paulson, H.L. and Bonini, N.M. (2000) Mechanisms of Chaperone Suppression of Polyglutamine Disease: Selectivity, Synergy and Modulation of Protein Solubility in Drosophila. Human Molecular Genetics, 9, 2811-2820. https://doi.org/10.1093/hmg/9.19.2811
Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K. and Hartl, F.U. (2000) Hsp70 and Hsp40 Chaperones Can Inhibit Self-Assembly of Polyglutamine Proteins into Amyloid-Like Fibrils. Proceedings of the National Academy of Sciences of the United States of America, 97, 7841-7846. https://doi.org/10.1073/pnas.140202897
Bailey, C.K., Andriola, I.F., Kampinga, H.H. and Merry, D.E. (2002) Molecular Chaperones Enhance the Degradation of Expanded Polyglutamine Repeat Androgen Receptor in a Cellular Model of Spinal and Bulbar Muscular Atrophy. Human Molecular Genetics, 11, 515-523. https://doi.org/10.1093/hmg/11.5.515
Verhoef, L.G., Lindsten, K., Masucci, M.G. and Dantuma, N.P. (2002) Aggregate Formation Inhibits Proteasomal Degradation of Polyglutamine Proteins. Human Molecular Genetics, 11, 2689-2700. https://doi.org/10.1093/hmg/11.22.2689
Yoshida, H., Yoshizawa, T., Shibasaki, F., Shoji, S. and Kanazawa, I. (2002) Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado-Joseph Disease Gene Product with an Expanded Polyglutamine Stretch. Neurobiology of Disease, 10, 88-99. https://doi.org/10.1006/nbdi.2002.0502
Rubinsztein, D.C. (2006) The Roles of Intracellular Protein-Degradation Pathways in Neurodegeneration. Nature, 443, 780-786. https://doi.org/10.1038/nature05291
Boy, J., Schmidt, T., Wolburg, H., Mack, A., Nuber, S., Bottcher, M., Schmitt, I., Holzmann, C., Zimmermann, F., Servadio, A. and Riess, O. (2009) Reversibility of Symptoms in a Conditional Mouse Model of Spinocerebellar Ataxia Type 3. Human Molecular Genetics, 18, 4282-4295. https://doi.org/10.1093/hmg/ddp381
Ravikumar, B., Duden, R. and Rubinsztein, D.C. (2002) Aggregate-Prone Proteins with Polyglutamine and Polyalanine Expansions Are Degraded by Autophagy. Human Molecular Genetics, 11, 1107-1117. https://doi.org/10.1093/hmg/11.9.1107
Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S., Oroz, L.G., Scaravilli, F., Easton, D.F., Duden, R., O’Kane, C.J. and Rubinsztein, D.C. (2004) Inhibition of mTOR Induces Autophagy and Reduces Toxicity of Polyglutamine Expansions in Fly and Mouse Models of Huntington Disease. Nature Genetics, 36, 585-595. https://doi.org/10.1038/ng1362
Berger, Z., Ravikumar, B., Menzies, F.M., Oroz, L.G., Underwood, B.R., Pangalos, M.N., Schmitt, I., Wullner, U., Evert, B.O., O’Kane, C.J. and Rubinsztein, D.C. (2006) Rapamycin Alleviates Toxicity of Different Aggregate-Prone Proteins. Human Molecular Genetics, 15, 433-442. https://doi.org/10.1093/hmg/ddi458
Menzies, F.M., Huebener, J., Renna, M., Bonin, M., Riess, O. and Rubinsztein, D.C. (2010) Autophagy Induction Reduces Mutant Ataxin-3 Levels and Toxicity in a Mouse Model of Spinocerebellar Ataxia Type 3. Brain, 133, 93-104. https://doi.org/10.1093/brain/awp292
Jia, D.D., Zhang, L., Chen, Z., Wang, C.R., Huang, F.Z., Duan, R.H., Xia, K., Tang, B.S. and Jiang, H. (2013) Lithium Chloride Alleviates Neurodegeneration Partly by Inhibiting Activity of GSK3beta in a SCA3 Drosophila Model. Cerebellum (London, England), 12, 892-901. https://doi.org/10.1007/s12311-013-0498-3
Saute, J.A., de Castilhos, R.M., Monte, T.L., Schumacher-Schuh, A.F., Donis, K.C., D’Avila, R., Souza, G.N., Russo, A.D., Furtado, G.V., Gheno, T.C., de Souza, D.O., Portela, L.V., Saraiva-Pereira, M.L., Camey, S.A., Torman, V.B., de Mello Rieder, C.R. and Jardim, L.B. (2014) A Randomized, Phase 2 Clinical Trial of Lithium Carbonate in Machado-Joseph Disease. Movement Disorders, 29, 568-573. https://doi.org/10.1002/mds.25803
Duarte-Silva, S., Neves-Carvalho, A., Soares-Cunha, C., Teixeira-Castro, A., Oliveira, P., Silva-Fernandes, A. and Maciel, P. (2014) Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease. The Cerebellum, 13, 713-727. https://doi.org/10.1007/s12311-014-0589-9
Lin, C.H., Wu, Y.R., Yang, J.M., Chen, W.L., Chao, C.Y., Chen, I.C., Lin, T.H., Wu, Y.C., Hsu, K.C., Chen, C.M., Lee, G.C., Hsieh-Li, H.M., Lee, C.M. and Lee-Chen, G.J. (2016) Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3. CNS & Neurological Disorders Drug Targets, 15, 351-359. https://doi.org/10.2174/1871527314666150821101522
Wang, H.L., Hu, S.H., Chou, A.H., Wang, S.S., Weng, Y.H. and Yeh, T.H. (2013) H1152 Promotes the Degradation of Polyglutamine-Expanded Ataxin-3 or Ataxin-7 Independently of Its ROCK-Inhibiting Effect and Ameliorates Mutant Ataxin-3-Induced Neurodegeneration in the SCA3 Transgenic Mouse. Neuropharmacology, 70, 1-11. https://doi.org/10.1016/j.neuropharm.2013.01.006
Chen, X., Tang, T.S., Tu, H., Nelson, O., Pook, M., Hammer, R., Nukina, N. and Bezprozvanny, I. (2008) Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3. The Journal of Neuroscience, 28, 12713-12724. https://doi.org/10.1523/JNEUROSCI.3909-08.2008
Makarewicz, D., Zieminska, E. and Lazarewicz, J.W. (2003) Dantrolene Inhibits NMDA-Induced 45Ca Uptake in Cultured Cerebellar Granule Neurons. Neurochemistry International, 43, 273-278. https://doi.org/10.1016/S0197-0186(03)00012-3
Lin, C.M., Neeru, S., Doufas, A.G., Liem, E., Muneer Shah, Y., Wadhwa, A., Lenhardt, R., Bjorksten, A., Taguchi, A., Kabon, B., Sessler, D.I. and Kurz, A. (2004) Dantrolene Reduces the Threshold and Gain for Shivering. Anesthesia and Analgesia, 98, 1318-1324. https://doi.org/10.1213/01.ANE.0000108968.21212.D7
Muehlschlegel, S., Rordorf, G. and Sims, J. (2011) Effects of a Single Dose of Dantrolene in Patients with Cerebral Vasospasm after Subarachnoid Hemorrhage: A Prospective Pilot Study. Stroke, 42, 1301-1306. https://doi.org/10.1161/STROKEAHA.110.603159
Cunha, R.A. and Agostinho, P.M. (2010) Chronic Caffeine Consumption Prevents Memory Disturbance in Different Animal Models of Memory Decline. Journal of Alzheimer’s Disease, 20, S95-S116. https://doi.org/10.3233/JAD-2010-1408
Goncalves, N., Simoes, A.T., Cunha, R.A. and de Almeida, L.P. (2013) Caffeine and Adenosine A2A Receptor Inactivation Decrease Striatal Neuropathology in a Lentiviral-Based Model of Machado-Joseph Disease. Annals of Neurology, 73, 655-666. https://doi.org/10.1002/ana.23866
Popoli, P., Blum, D., Martire, A., Ledent, C., Ceruti, S. and Abbracchio, M.P. (2007) Functions, Dysfunctions and Possible Therapeutic Relevance of Adenosine A2A Receptors in Huntington’s Disease. Progress in Neurobiology, 81, 331-348. https://doi.org/10.1016/j.pneurobio.2006.12.005
Martinez-Morales, P.L., Revilla, A., Ocana, I., Gonzalez, C., Sainz, P., McGuire, D. and Liste, I. (2013) Progress in Stem Cell Therapy for Major Human Neurological Disorders. Stem Cell Reviews, 9, 685-699. https://doi.org/10.1007/s12015-013-9443-6
Jones, J., Jaramillo-Merchan, J., Bueno, C., Pastor, D., Viso-Leon, M. and Martinez, S. (2010) Mesenchymal Stem Cells Rescue Purkinje Cells and Improve Motor Functions in a Mouse Model of Cerebellar Ataxia. Neurobiology of Disease, 40, 415-623. https://doi.org/10.1016/j.nbd.2010.07.001